| scholarly article | Q13442814 |
| P50 | author | Dan M Granoff | Q48255905 |
| P2093 | author name string | Peter T Beernink | |
| Sanjay Ram | |||
| Rolando Pajon | |||
| Jutamas Shaughnessy | |||
| Emily M Braga | |||
| P2860 | cites work | Rational design of a meningococcal antigen inducing broad protective immunity | Q27670780 |
| The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement | Q28474974 | ||
| Interpreting flow cytometry data: a guide for the perplexed | Q31045140 | ||
| Review of meningococcal group B vaccines | Q33646965 | ||
| Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates | Q33695485 | ||
| Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding | Q33962709 | ||
| Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. | Q33999628 | ||
| Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity | Q34009161 | ||
| Immunogenicity of 2 Investigational Serogroup B Meningococcal Vaccines in the First Year of Life | Q58493020 | ||
| Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. | Q64901018 | ||
| Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway | Q68322753 | ||
| Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides | Q72283649 | ||
| Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines | Q73203844 | ||
| Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease | Q84554545 | ||
| Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine | Q84588187 | ||
| An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups | Q84729221 | ||
| Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa | Q34039044 | ||
| Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains | Q34185172 | ||
| Effect of Factor H-Binding Protein Sequence Variation on Factor H Binding and Survival ofNeisseria meningitidisin Human Blood | Q34484616 | ||
| Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. | Q34594327 | ||
| Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease | Q34729067 | ||
| Microbial complement inhibitors as vaccines | Q34977385 | ||
| A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination | Q34993283 | ||
| Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. | Q35043042 | ||
| A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines | Q35066132 | ||
| Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding | Q35191862 | ||
| Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development | Q35198778 | ||
| Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870 | Q36370598 | ||
| The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance | Q36470692 | ||
| Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870 | Q36638451 | ||
| A surveillance network for meningococcal disease in Europe. | Q36683965 | ||
| Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. | Q36683979 | ||
| Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines | Q36710765 | ||
| Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera | Q37075472 | ||
| Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2 | Q37099232 | ||
| Vaccine potential of the Neisseria meningitidis 2086 lipoprotein | Q37115883 | ||
| Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin | Q37126987 | ||
| Serogroup B meningococcal vaccines-an unfinished story | Q37683962 | ||
| A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. | Q38478418 | ||
| Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease | Q39920363 | ||
| Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development | Q40513524 | ||
| Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine | Q40564309 | ||
| Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis | Q48761076 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P304 | page(s) | e1002688 | |
| P577 | publication date | 2012-05-10 | |
| P1433 | published in | PLOS Pathogens | Q283209 |
| P1476 | title | The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein | |
| P478 | volume | 8 |
| Q92859964 | A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine |
| Q35658277 | A Mutant Library Approach to Identify Improved Meningococcal Factor H Binding Protein Vaccine Antigens |
| Q35748972 | A Newly-Identified Polymorphism in Rhesus Macaque Complement Factor H Modulates Binding Affinity for Meningococcal FHbp |
| Q39143108 | A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA). |
| Q36521563 | A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine |
| Q57808501 | A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed Factor H binding protein elicits gonococcal bactericidal antibodies |
| Q36354851 | A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes |
| Q35181636 | A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice |
| Q37008156 | Bacillus anthracis Spore Surface Protein BclA Mediates Complement Factor H Binding to Spores and Promotes Spore Persistence |
| Q35965207 | Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine |
| Q36211092 | Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. |
| Q37124721 | Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? |
| Q36385023 | Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine |
| Q90128021 | Effect of complement Factor H on antibody repertoire and protection elicited by meningococcal capsular group B vaccines containing Factor H binding protein |
| Q37277250 | Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding |
| Q42251621 | Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles. |
| Q35777766 | Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein |
| Q34592926 | Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines |
| Q34237895 | Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding |
| Q35922195 | Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles |
| Q36513433 | Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice |
| Q37037083 | Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines |
| Q34376170 | Meningococcal disease and the complement system |
| Q37401146 | Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice |
| Q26864388 | Molecular basis of host specificity in human pathogenic bacteria |
| Q34785389 | Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa |
| Q38363907 | Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. |
| Q37505447 | Portrait: coincidences, convergences and opportunities |
| Q28087528 | Protein Crystallography in Vaccine Research and Development |
| Q90227075 | Role of Gonococcal Neisserial Surface Protein A (NspA) in Serum Resistance and Comparison of Its Factor H Binding Properties with Those of Its Meningococcal Counterpart |
| Q40955783 | Some Gram-negative Lipoproteins Keep Their Surface Topology When Transplanted from One Species to Another and Deliver Foreign Polypeptides to the Bacterial Surface |
| Q38335257 | The Long Road to an Effective Vaccine for Meningococcus Group B (MenB). |
| Q39182985 | There Is a Method to the Madness: Strategies to Study Host Complement Evasion by Lyme Disease and Relapsing Fever Spirochetes |
Search more.